FindTrial
Sign In

Change in Residual beta cell function in Newly diagnosed T1 diabetes children receiving lansoprazole and vitamin D supplementation

An observational pilot study on the change in residual beta cell function in children with newly diagnosed Type 1 Diabetes receiving Lansoprazole and vitamin D supplementation.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/07/034989
Enrollment
40
Registered
2021-07-19
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E101- Type 1 diabetes mellitus with ketoacidosis

Interventions

None listed

Sponsors

Raghunatha Reddy
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Newly diagnosed patients with T1Diabetes Autoantibodies positivity Baseline c peptide 0.5 ng/ml Children receiving lansoprazole for dyspeptic symtptoms

Exclusion criteria

Exclusion criteria: Presence of other autoimmune disease Vitamin D deficiency Patient on vitamin D /other multivitamin supplementation Children with preexisting renal /hepatic disease

Design outcomes

Primary

MeasureTime frame
Changes in FCP levels from baseline to study pointTimepoint: 0,3,6 months—

Secondary

MeasureTime frame
change in: 1. Mean total insulin dose 2. Mean HbA1c levels 3. Mean blood glucose levelsTimepoint: 0 , 3 , 6 months—

Countries

India

Contacts

Public ContactRaghunatha Reddy

PGIMER

drdevidayal@gmail.com9872072472

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026